THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT TO EXCLUSIVE LICENSE...Exclusive License Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment to the Exclusive License Agreement (the "Amendment') is entered into as of September 7, 2018 (the "Amendment Effective Date") by and between Entera Health, Inc., an Iowa Corporation, having an address at 2425 SE Oak Tree Court, Ankeny, Iowa 50021 (the ''Licensor''), and RedHill Biopharma, Inc. a Delaware corporation, having an address at 8045 Arco Corporate Drive, Suite 120, Raleigh, North Carolina 27617, along with all Affiliates thereof (as defined in that certain Exclusive License Agreement dated as of April 4, 2017 between the parties hereto (the "Agreement")) ("Licensee"). Unless otherwise specifically defined in this Amendment, any term used in this Amendment which is defined in the Agreement shall have the meaning assigned to it in the Agreement.
AMENDMENT NO. 1 TO AGREEMENTAgreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No.1 to Agreement is made as of February 26, 2018 (the “Amendment Effective Date”) by and between RedHill Biopharma Ltd. (“RedHill”) and Salix Pharmaceuticals, Inc. (“Salix”).
First Addendum Exclusive Licensing AgreementExclusive Licensing Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This First Addendum to the Agreement (as defined below) is made and entered into between Licensor and Licensee as of the Effective Date of the Agreement.
Amendment #5 To EXCLUSIVE LICENSE AGREEMENT Apogee Biotechnology Corporation and RedHill Biopharma Ltd.Exclusive License Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment is entered into effective as of the date of the last signature below (the “Effective Date”) by and between RedHill Biopharma Ltd. (“RedHill”) and Apogee Biotechnology Corporation (“Apogee”) to amend the terms of that Exclusive License Agreement entered into by the parties effective March 30, 2015 (“Agreement”).
THE SYMBOL "[****]" DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION AMENDMENT NO. 1 TO EXCLUSIVE...Exclusive Commercialization Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment No.1 to Exclusive Commercialization Agreement is made effective as of August 24, 2018 by and between RedHill Biopharma Ltd. (“RedHill”) and Concordia Pharmaceuticals Inc., by way of its Barbados branch (“Concordia”).
Amendment #4 To EXCLUSIVE LICENSE AGREEMENT Apogee Biotechnology Corporation and RedHill Biopharma LtdExclusive License Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment is entered into effective as of the date of the last signature below (the “Effective Date”) by and between RedHill Biopharma Ltd (“RedHill”) and Apogee Biotechnology Corporation (“Apogee”) to amend the terms of that Exclusive License Agreement entered into by the parties effective March 30, 2015 (“Agreement”).
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment to Asset Purchase Agreement (this “Amendment”) is made as of 27 February 2014 (the “Amendment Effective Date”), by and among RedHill Biopharma Ltd., an Israeli company having its principal place of business at 21 Ha’arba’a Street, Tel-Aviv 64739, Israel (“RedHill”), and Giaconda Limited ACN 108 088 517, an Australian public limited company having its registered office at Ground Floor, 44 East Street, Five Dock, NSW 2046, Australia (“Giaconda”). Each of RedHill and Giaconda is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
Amendment #1 To EXCLUSIVE LICENSE AGREEMENT Apogee Biotechnology Corporation and RedHill Biopharma LtdExclusive License Agreement • February 26th, 2019 • RedHill Biopharma Ltd. • Pharmaceutical preparations
This Amendment is entered into effective as of the date of the last signature below (the "Effective Date") by and between RedHill Biopharma Ltd ("RedHill") and Apogee Biotechnology Corporation ("Apogee") to amend the terms of that Exclusive License Agreement entered into by the parties effective March 30, 2015 ("Agreement").
